INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) releases its total number of shares outstanding as well as its voting rights as at July 1, 2012

Transparency directive : regulatory news

09/07/2012 07:15

PRESS RELEASE

     NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT JULY 1, 2012

Marseilles, July 9, 2012

Pursuant to the article L. 233-8 II of the French " Code de Commerce " and the
article 223-16 of the French stock-market authorities (Autorité des Marchés
Financiers, or "AMF") charter, Innate Pharma SA (the "Company" - Euronext
Paris: FR0010331421 - IPH) releases its total number of shares outstanding as
well as its voting rights as at July 1, 2012:

   Total number of shares outstanding:               37,935,894
   Total number of theoretical voting rights (1):    37,935,894
   Total number of exercisable voting rights (2):    37 556 847

(1) The total number of theoretical voting rights (or "gross" voting rights) is
used as the basis for calculating the crossing of shareholding thresholds. In
accordance with Article 223-11 of the AMF General Regulation, this number is
calculated on the basis of all shares to which voting rights are attached,
including shares whose voting rights have been suspended.

(2) The total number of exercisable voting rights (or "net" voting rights) is
calculated without taking into account the shares with suspended voting rights,
in this case, shares held by the Company in the context of a liquidity
agreement. It is released so as to ensure that the market is adequately
informed, in accordance with the recommendation made by the AMF on July 17,
2007.

About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approach has been validated by licence agreements with
two major pharmaceutical companies, Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate
Pharma is based in Marseilles, France, and had 81 employees as at
June 30, 2012.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code                      FR0010331421
Ticker code                    IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:
Innate Pharma                            ATCG Press
Laure-Hélène Mercier                     Marielle Bricman
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87              Mob.: +33 (0)6 26 94 18 53
investors@innate-pharma.com              mb@atcg-partners.com

120701_IPH_number_of_shares_as_of_July_1_2012.doc

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) releases its total number of shares outstanding as well as its voting rights as at July 1, 2012

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories